UOC
RYTM icon

UBS O'Connor’s Rhythm Pharmaceuticals RYTM Stock Holding History

UBS O'Connor’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$26K – 556
2024
Q3 		$26K Buy
+20,000
New +$958K ﹤0.01% 437
2023
Q4 		– Sell
-45,000
Closed -$49.5K – 587
2023
Q3 		$49.5K Buy
+45,000
New +$1.01M ﹤0.01% 488

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS O'Connor's RYTM Position: Q4 2023 in Review

UBS O'Connor sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2023, closing a stake of 30,000 shares — an estimated $946K sold.

UBS O'Connor first reported a position in RYTM in Q3 2022 and held it in 3 quarters. The position peaked at $1.77M in Q3 2022. 168 funds tracked by Wall St. Rank hold RYTM as of Q4 2023.

  • UBS O'Connor reported no remaining Rhythm Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 30,000 Rhythm Pharmaceuticals shares in Q4 2023, an estimated $946K.
  • UBS O'Connor first reported a position in Rhythm Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • UBS O'Connor's Rhythm Pharmaceuticals position peaked at $1.77M in Q3 2022.
  • 168 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.